BEAM vs. CRSP
Compare and contrast key facts about Beam Therapeutics Inc. (BEAM) and CRISPR Therapeutics AG (CRSP).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BEAM or CRSP.
Key characteristics
| BEAM | CRSP | |
|---|---|---|
| YTD Return | -11.46% | -11.09% |
| 1Y Return | -22.66% | 7.02% |
| 3Y Return (Ann) | -32.14% | -24.03% |
| Sharpe Ratio | -0.28 | 0.20 |
| Daily Std Dev | 71.66% | 58.96% |
| Max Drawdown | -86.76% | -81.61% |
| Current Drawdown | -81.96% | -73.50% |
Fundamentals
| BEAM | CRSP | |
|---|---|---|
| Market Cap | $1.95B | $4.67B |
| EPS | -$1.72 | -$1.94 |
| Revenue (TTM) | $377.71M | $371.21M |
| Gross Profit (TTM) | -$250.67M | -$570.70M |
| EBITDA (TTM) | -$156.47M | -$202.70M |
Correlation
The correlation between BEAM and CRSP is 0.68, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
BEAM vs. CRSP - Performance Comparison
The year-to-date returns for both investments are quite close, with BEAM having a -11.46% return and CRSP slightly higher at -11.09%. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
BEAM vs. CRSP - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Beam Therapeutics Inc. (BEAM) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BEAM vs. CRSP - Dividend Comparison
Neither BEAM nor CRSP has paid dividends to shareholders.
Drawdowns
BEAM vs. CRSP - Drawdown Comparison
The maximum BEAM drawdown since its inception was -86.76%, which is greater than CRSP's maximum drawdown of -81.61%. Use the drawdown chart below to compare losses from any high point for BEAM and CRSP. For additional features, visit the drawdowns tool.
Volatility
BEAM vs. CRSP - Volatility Comparison
Beam Therapeutics Inc. (BEAM) has a higher volatility of 13.14% compared to CRISPR Therapeutics AG (CRSP) at 10.72%. This indicates that BEAM's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
BEAM vs. CRSP - Financials Comparison
This section allows you to compare key financial metrics between Beam Therapeutics Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities